maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary dis. e (COPD) including chronic bronchitis and emphysema. SYMBICORT 160/4.5 is the only …

Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) reduces asthma exacerbations and symptoms versus fixed-dose regimens plus short-acting beta (2)-agonists …

2009年3月2日 · AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for the …

2016年7月28日 · Symbicort® Inhalation Aerosol Generic Name: Budesonide and formoterol fumarate dihydrate Sponsor: AstraZeneca Route of Administration: Inhalation

SYMBICORT pMDI was approved in July 2006 for the long-term maintenance treatment of asthma in patients 12 years of age and older (NDA 21-929). It was approved in February 2009 …

The product under discussion, Symbicort Inhalation Aerosol [Symbicort], is an HFA-propelled metered dose inhaler [MDI]. However, some products and formulations used prior to 2007 used

商品名:symbicort,活性成分:budesonide; formoterol fumarate dihydrate,申请号:021929,申请人:astrazeneca

2017年1月26日 · Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting bronchodilator indicated for the long-term maintenance treatment of asthma and …

Symbicort is a combination inhaler used in asthma and chronic obstructive pulmonary disease (COPD) that contains budesonide and formoterol. In asthma, Symbicort can be used as fixed …

Symbicort with the regimens 160/4.5 mg/inhalation has higher efficacy in reducing asthma symptom and improving its control compared with low doses of this drug and with Pulmicort. …